| PP100326002467 |
Diamyd Medical AB |
Diamyd® |
retogatein |
Induction .. |
Type 1 dia.. |
Phase III, Phase II, Phase II |
View Details
|
| PP111128008875 |
DiaMedica Inc. |
DM199 |
recombinant human tissue kallikrein (rhKLK-1); rinvecalinase alfa |
To protect.. |
Acute isch.. |
Phase III, Phase II, Phase II, Phase II, Phase I |
View Details
|
| PP160714014456 |
Dong-A ST |
DA-8010 |
velufenacin |
A novel, p.. |
Overactive.. |
Phase III |
View Details
|
| PP160714014457 |
Dong-A ST |
DA-1241 |
|
A G protei.. |
Type 2 dia.. |
Phase I completed, Phase II |
View Details
|
| PP160725014525 |
Eli Lilly and Company |
LY3154207 |
mevidalen |
A dopamine.. |
Symptomati.. |
Phase II |
View Details
|
| PP160919014860 |
CervoMed Inc. (since Aug 2023), EIP Pharma, LLC |
VX-745 |
neflamapimod |
To inhibit.. |
Dementia w.. |
Phase II completed, Phase II, Phase II |
View Details
|
| PP161222015363 |
Adverum Biotechnologies, An Eli Lilly |
ADVM-022 |
AAV.7m8-aflibercept gene; ixoberogene soroparvovec (ixo-vec) |
Gene repla.. |
Wet age-re.. |
Phase III, Phase II, Phase I |
View Details
|
| PP170905016106 |
AstraZeneca |
MEDI3506 |
tozorakimab |
An anti-IL.. |
Chronic ob.. |
Phase III completed, Phase III, Phase II, Phase II, Phase II |
View Details
|
| PP180928016713 |
Chugai Pharmaceutical Co., Ltd. |
Foundayo, OWL833, LY3502970 |
orforglipron calcium |
A non-pept.. |
Obesity, D.. |
Approved, NDA, Phase III, Phase III, Phase III, Phase III |
View Details
|
| PP181018016749 |
Eli Lilly and Company |
Mounjaro, LY3298176 |
tirzepatide |
A coagonis.. |
Type II di.. |
Approved, Approved, Phase III, Phase III |
View Details
|